Clinical Trials Browser

Colorectal Neoplasms × regorafenib × 1 year × Clear all

NCT07071961 2026-06-05

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Phase 2 Suspended

Gastrointestinal

Colorectal Neoplasms

NCT05064059 2026-05-26

MK-4280A-007

Phase 3 Completed

441 enrolled 24 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04787341 2026-05-20

PARERE

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05198934 2026-04-27

CodeBreak300

Phase 3 Completed

160 enrolled 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 Recruiting

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT02310477 2026-03-13

REBECCA

Gastrointestinal

Colorectal Neoplasms

NCT07137390 2026-03-11

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT06137170 2026-03-02

RegoSeq

Gastrointestinal

Colorectal Neoplasms

NCT03828799 2026-02-27

FOLFIRINOX-R

Phase 1/2 Completed

13 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT03712943 2026-02-09

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05672316 2026-01-28

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07343791 2026-01-15

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06283134 2026-01-07

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Phase 2 Active not recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07213570 2025-12-17

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03377361 2025-12-03

CheckMate 9N9

Phase 1/2 Completed

325 enrolled 31 charts

Gastrointestinal

Colorectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Phase 3 Completed

94 enrolled 15 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03829462 2025-11-21

NEXT-REGIRI

Phase 3 Active not recruiting

377 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT05839951 2025-11-12

STAR-T

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05425940 2025-10-23

STELLAR-303

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07134205 2025-08-21

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05328908 2025-08-13

RELATIVITY-123

Phase 3 Terminated

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03657641 2025-07-04

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

123 enrolled 21 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms